The American Healthcare Conundrum

Original Article ↗ Hacker News Discussion ↗

New analysis of U.S. hospital cost reports suggests that commercial insurers pay roughly 2.5x Medicare rates on average, with nonprofit hospitals showing some of the highest markups over actual costs. Commenters debate why American healthcare spending is so far above peer countries, pointing variously to Medicare’s pricing power, opaque hospital and drug pricing, administrative bloat, profit caps that create perverse incentives, and structural shortages of medical staff. Many argue that fragmented insurance and misaligned incentives—not just patient behavior or physician pay—make the system both unusually expensive and difficult to reform, with proposals ranging from all‑payer rate setting to single‑payer models and stricter regulation of intermediaries like pharmacy benefit managers.

Hospital pricing and markups

  • Author’s pipeline on CMS HCRIS data (3,193 hospitals, FY2023) finds very high markups on cost: median 2.6× overall, ~3.96× for nonprofits vs ~2.4× for for‑profit and ~1.9× for government hospitals.
  • Some argue this undermines the “cross‑subsidizing Medicare” narrative and instead reflects market power and consolidation; others still see cross‑subsidy as real, especially for Medicaid and underpaid services.
  • Huge variation in cost‑to‑charge ratios even among similar hospitals suggests arbitrary or market‑power‑driven pricing, not cost.

Medicare vs commercial insurers

  • Several commenters say Medicare is among the best, most reliable payers, with transparent formulas and lump‑sum or value‑based payments; some private contracts even peg to a % of Medicare.
  • Others insist Medicare and especially Medicaid underpay, forcing providers to recoup from commercial plans; some hospitals cap Medicare/Medicaid patients or rely on portfolio effects.
  • There’s disagreement over how much of US overpricing is due to Medicare’s monopsony vs private insurer weakness in local hospital markets.

ACA, medical loss ratios, and insurer incentives

  • One camp claims ACA’s 80–85% minimum medical loss ratio (MLR) makes insurers want higher total spending: 20% of a bigger pie.
  • Critics counter that margins are low (single‑digit %), markets are somewhat competitive, and much large‑employer coverage is self‑funded so the “spend more to earn more” story is oversimplified.
  • Vertical integration (insurer + PBM + clinics/pharmacies) lets conglomerates count internal transfers as “medical spend,” potentially gaming MLR.

PBMs and drug pricing

  • PBMs are widely portrayed as a major distortion: spread pricing, rebate games, steering to owned pharmacies, and markups that make cash/discount‑card prices lower than insured prices.
  • Some argue high US drug prices subsidize global pharma R&D; others see that as industry propaganda and emphasize marketing and lobbying.

Administrative overhead and complexity

  • Administrative/billing overhead is described as 15–30% of US health spending, far above peers, with physicians losing significant time to billing.
  • Medicare’s low visible admin overhead is said to be partially offloaded to providers (e.g., complex cost reports and documentation).

Provider pay, workforce, and malpractice

  • US doctors and nurses earn much more than in many countries; some see deliberate supply constraints (med school slots, residencies, AMA influence) and high malpractice costs as drivers.
  • Others note physician income is <10% of total spend, so high pay is “a factor but not the main one.”

International comparisons and lifestyle

  • Japan and European systems are repeatedly contrasted: lower per‑capita and %‑GDP spending with equal or better outcomes, though commenters note huge lifestyle differences (diet, obesity, transit use) and demographic structure.
  • Some argue US outcomes look better if you adjust for income or focus on specific subpopulations; others highlight that almost all rich countries outperform the US on cost‑for‑outcome.

Structure, politics, and reform ideas

  • Widely shared themes: misaligned incentives, regulatory capture, lobbying (~$750M/year cited), and fragmentation across payers.
  • Proposed directions include single‑payer or public option, all‑payer rate‑setting (Maryland as example), stronger price transparency, decoupling insurance from employment, tort reform, and tackling food/agriculture drivers of metabolic disease.
  • There is broad agreement the system is deeply broken; disagreement centers on whether insurers, providers, regulation, or broader political economy are primary culprits, and on how radical reforms can be implemented without collapse.